Literature DB >> 16143485

Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance.

Sang Kyoon Kim1, Kwangmeyung Kim, Seulki Lee, Kyeongsoon Park, Jae Hyung Park, Ick Chan Kwon, Kuiwon Choi, Choong-Yong Kim, Youngro Byun.   

Abstract

We validated the application of the surface plasmon resonance (SPR) technique to reliably determine adhesion of drugs to the intestinal wall using heparin-DOCA conjugates, developed to enhance the oral absorption of poorly absorbed heparin. In this study, heparin conjugates, or deoxycholyl-heparin (H-DOCA) and bisdeoxycholyl-heparin (H-bis-DOCA), were synthesized by covalently coupling the synthesized succinimido deoxycholate (DOCA-NHS) or succinimido bis-deoxycholyl-L-lysine (DOCA-bis-NHS) to amine groups of heparin, and their physicochemical and biological properties were evaluated. To mimic the duodenal and ileal surfaces, duodenal and ileal brush border membrane (BBM) vesicles isolated from Sprauge-Dawley (SD) rats were immobilized onto a biosensor chip composed of dextran derivatives with modified lipophilic residues. The adhesion of heparin conjugates on the BBM surface was evaluated by measuring the SPR response signal. The adhesion of heparin conjugates was significantly dependent on the conjugated DOCA molecules: that is, they showed higher adhesion signal on the ileal BBM surface than that on the duodenal BBM surface. In particular, the solubilized heparin conjugates in DMSO solution presented significantly increased adhesion affinity on the ileal BBM surface. The adhesion of heparin conjugates on the intestinal surfaces was successfully assayed using the surface plasmon resonance technique with the sensor chip on which BBM vesicles were immobilized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143485     DOI: 10.1016/j.jpba.2005.06.014

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically Ill patients.

Authors:  Young R Lee; Delilah D Blanco
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

2.  Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin.

Authors:  Jung Seok Lee; Patrick Han; Rabib Chaudhury; Shihan Khan; Sean Bickerton; Michael D McHugh; Hyun Bong Park; Alyssa L Siefert; Gerald Rea; José M Carballido; David A Horwitz; Jason Criscione; Karlo Perica; Robert Samstein; Ragy Ragheb; Dongin Kim; Tarek M Fahmy
Journal:  Nat Biomed Eng       Date:  2021-10-06       Impact factor: 25.671

3.  Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.

Authors:  Dong Yun Lee; Sung Won Lee; Sang Kyoon Kim; Myungjin Lee; Hyo Won Chang; Hyun Tae Moon; Youngro Byun; Sang Yoon Kim
Journal:  Pharm Res       Date:  2009-10-15       Impact factor: 4.200

Review 4.  Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.

Authors:  Nipa Banik; Seong-Bin Yang; Tae-Bong Kang; Ji-Hong Lim; Jooho Park
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 5.923

Review 5.  Strategies to Overcome Heparins' Low Oral Bioavailability.

Authors:  Ana Rita Neves; Marta Correia-da-Silva; Emília Sousa; Madalena Pinto
Journal:  Pharmaceuticals (Basel)       Date:  2016-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.